Abetimus
A synthetic drug used in the treatment of systemic lupus erythematosus
Abetimus is a synthetic immunosuppressive drug designed for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease characterized by the body's immune system attacking its own tissues. Abetimus is specifically engineered to reduce the production of anti-double-stranded DNA antibodies, which are implicated in the pathogenesis of SLE.
Mechanism of Action[edit | edit source]
Abetimus functions by mimicking the structure of double-stranded DNA (dsDNA), thereby acting as a decoy for the B cells that produce anti-dsDNA antibodies. By binding to these B cells, abetimus prevents them from producing harmful antibodies that can lead to tissue damage in patients with SLE. This mechanism helps in reducing the inflammatory response and subsequent organ damage associated with the disease.
Clinical Use[edit | edit source]
Abetimus is primarily used in patients with SLE who have high levels of anti-dsDNA antibodies. It is administered as part of a comprehensive treatment plan that may include other immunosuppressants, corticosteroids, and antimalarial drugs like hydroxychloroquine. The goal of treatment with abetimus is to achieve disease remission and prevent flare-ups of SLE symptoms.
Side Effects[edit | edit source]
Common side effects of abetimus include injection site reactions, such as redness and swelling, as well as flu-like symptoms such as fever and fatigue. More serious side effects can include allergic reactions and increased risk of infections due to its immunosuppressive action.
Development and Approval[edit | edit source]
Abetimus was developed as a novel approach to specifically target the pathogenic antibodies in SLE. Its development involved extensive clinical trials to assess its efficacy and safety. However, its approval status may vary by country, and it is important for healthcare providers to consider the latest guidelines and research when prescribing this medication.
Related pages[edit | edit source]
Abetimus
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
